BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/15/2024 2:49:03 AM | Browse: 233 | Download: 1168
 |
Received |
|
2023-10-27 07:05 |
|
Peer-Review Started |
|
2023-10-27 07:06 |
|
First Decision by Editorial Office Director |
|
2024-01-06 07:17 |
|
Return for Revision |
|
2024-01-06 07:17 |
|
Revised |
|
2024-01-24 08:05 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-03-27 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-03-27 04:53 |
|
Articles in Press |
|
2024-03-27 04:53 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-14 12:41 |
|
Publish the Manuscript Online |
|
2024-06-15 02:49 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Basic Study |
| Article Title |
Complement factor I knockdown inhibits colon cancer development by affecting Wnt/β-catenin/c-Myc signaling pathway and glycolysis
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Yong-Jun Du, Yue Jiang, Yan-Mei Hou and Yong-Bo Shi |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Yong-Bo Shi, MM, Associate Chief Physician, Department of Proctology, Zigong Hospital of Traditional Chinese Medicine, No. 59 Machongkou Street, Da’an District, Zigong 643000, Sichuan Province, China. syb821004@163.com |
| Key Words |
Colon cancer; Immune infiltration; Complement factor I; Glycolysis; Wnt/β-catenin/c-Myc pathway |
| Core Tip |
We identified six hub immune infiltration-related differentially expressed genes, of which the expression of complement factor I (CFI), complement factor B, lymphoid enhancer binding factor 1, and SRY-related high-mobility-group box 4 were upregulated, whereas that of fatty acid-binding protein 1 and bone morphogenic protein-2 were downregulated. CFI knockdown inhibited HT29 and HCT116 cell proliferation, migration, invasion, and tumor growth in a colon cancer (CC) mouse model constructed from HT29 cells. CFI knockdown suppressed the expression of glycolysis-related proteins (glucose transporter type 1, hexokinase 2, lactate dehydrogenase A, and pyruvate kinase M2) and Wnt/β-catenin/c-Myc-related protein-expression levels (β-catenin and c-Myc). CFI knockdown suppressed glycolysis by inhibiting the Wnt/β-catenin/c-Myc signaling pathway. These findings delineate a potential therapeutic strategy for the clinical management of CC. |
| Publish Date |
2024-06-15 02:49 |
| Citation |
Du YJ, Jiang Y, Hou YM, Shi YB. Complement factor I knockdown inhibits colon cancer development by affecting Wnt/β-catenin/c-Myc signaling pathway and glycolysis. World J Gastrointest Oncol 2024; 16(6): 2646-2662 |
| URL |
https://www.wjgnet.com/1948-5204/full/v16/i6/2646.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v16.i6.2646 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
